Epithelial magnesium transport by TRPM6 is essential for prenatal development and adult survival

  1. Vladimir Chubanov  Is a corresponding author
  2. Silvia Ferioli
  3. Annika Wisnowsky
  4. David G Simmons
  5. Christin Leitzinger
  6. Claudia Einer
  7. Wenke Jonas
  8. Yuriy Shymkiv
  9. Harald Bartsch
  10. Attila Braun
  11. Banu Akdogan
  12. Lorenz Mittermeier
  13. Ludmila Sytik
  14. Friedrich Torben
  15. Vindi Jurinovic
  16. Emiel PC van der Vorst
  17. Christian Weber
  18. Önder A Yildirim
  19. Karl Sotlar
  20. Annette Schürmann
  21. Susanna Zierler
  22. Hans Zischka
  23. Alexey G Ryazanov
  24. Thomas Gudermann  Is a corresponding author
  1. Ludwig Maximilian University of Munich, Germany
  2. The University of Queensland, Australia
  3. Helmholtz Zentrum Munich, Germany
  4. German Institute of Human Nutrition, Germany
  5. Princeton Institute of Life Sciences, United States
  6. University of Würzburg, Germany
  7. LMU Munich, Germany
  8. Paracelsus Medical University, Austria

Abstract

Mg2+ regulates many physiological processes and signalling pathways. However, little is known about the mechanisms underlying the organismal balance of Mg2+. Capitalizing on a set of newly generated mouse models, we provide an integrated mechanistic model of the regulation of organismal Mg2+ balance during prenatal development and in adult mice by the ion channel TRPM6. We show that TRPM6 activity in the placenta and yolk sac is essential for embryonic development. In adult mice, TRPM6 is required in the intestine to maintain organismal Mg2+ balance, but is dispensable in the kidney. Trpm6 inactivation in adult mice leads to shortened lifespan, growth deficit and metabolic alterations indicative of impaired energy balance. Dietary Mg2+ supplementation not only rescues all phenotypes displayed by Trpm6-deficient adult mice, but also may extend the lifespan of wildtype mice. Hence, maintenance of organismal Mg2+ balance by TRPM6 is crucial for prenatal development and survival to adulthood.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Vladimir Chubanov

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    For correspondence
    vladimir.chubanov@lrz.uni-muenchen.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6042-4193
  2. Silvia Ferioli

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Annika Wisnowsky

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. David G Simmons

    School of Biomedical Sciences, The University of Queensland, St. Lucia, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4115-9371
  5. Christin Leitzinger

    Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum Munich, Neuherberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Claudia Einer

    Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum Munich, Neuherberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  7. Wenke Jonas

    Department of Experimental Diabetology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Yuriy Shymkiv

    Princeton Institute of Life Sciences, Princeton, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Harald Bartsch

    Institute of Pathology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Attila Braun

    Department of Vascular Medicine, University Hospital and Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Würzburg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Banu Akdogan

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Lorenz Mittermeier

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  13. Ludmila Sytik

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  14. Friedrich Torben

    Genome Analysis Center, Institute of Experimental Genetics, Helmholtz Zentrum Munich, Neuherberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  15. Vindi Jurinovic

    IBE, LMU Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  16. Emiel PC van der Vorst

    Institute for Cardiovascular Prevention, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  17. Christian Weber

    Institute for Cardiovascular Prevention, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
  18. Önder A Yildirim

    Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum Munich, Neuherberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  19. Karl Sotlar

    Institute of Pathology, Paracelsus Medical University, Salzburg, Austria
    Competing interests
    The authors declare that no competing interests exist.
  20. Annette Schürmann

    Department of Experimental Diabetology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany
    Competing interests
    The authors declare that no competing interests exist.
  21. Susanna Zierler

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4684-0385
  22. Hans Zischka

    Institute of Molecular Toxicology and Pharmacology, Helmholtz Zentrum Munich, Neuherberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  23. Alexey G Ryazanov

    Princeton Institute of Life Sciences, Princeton, United States
    Competing interests
    The authors declare that no competing interests exist.
  24. Thomas Gudermann

    Walther-Straub Institute of Pharmacology and Toxicology, Ludwig Maximilian University of Munich, Munich, Germany
    For correspondence
    thomas.gudermann@lrz.uni-muenchen.de
    Competing interests
    The authors declare that no competing interests exist.

Funding

Deutsche Forschungsgemeinschaft (TRR 152-P15)

  • Vladimir Chubanov

Deutsche Forschungsgemeinschaft (TRP 152-P15)

  • Thomas Gudermann

Deutsche Forschungsgemeinschaft (TRP 152-P14)

  • Susanna Zierler

Deutsche Forschungsgemeinschaft (SFB1123-A1)

  • Emiel PC van der Vorst
  • Christian Weber

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Experiments involving animals were done in accordance with the EU Animal Welfare Act and were approved by the local councils on animal care (permit No 55.2-1-54-2532-134-13 from Government of Oberbayern, Germany, and permit No 2347-15-2014 from State Ministry of Brandenburg, Germany).

Copyright

© 2016, Chubanov et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,459
    views
  • 545
    downloads
  • 102
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Vladimir Chubanov
  2. Silvia Ferioli
  3. Annika Wisnowsky
  4. David G Simmons
  5. Christin Leitzinger
  6. Claudia Einer
  7. Wenke Jonas
  8. Yuriy Shymkiv
  9. Harald Bartsch
  10. Attila Braun
  11. Banu Akdogan
  12. Lorenz Mittermeier
  13. Ludmila Sytik
  14. Friedrich Torben
  15. Vindi Jurinovic
  16. Emiel PC van der Vorst
  17. Christian Weber
  18. Önder A Yildirim
  19. Karl Sotlar
  20. Annette Schürmann
  21. Susanna Zierler
  22. Hans Zischka
  23. Alexey G Ryazanov
  24. Thomas Gudermann
(2016)
Epithelial magnesium transport by TRPM6 is essential for prenatal development and adult survival
eLife 5:e20914.
https://doi.org/10.7554/eLife.20914

Share this article

https://doi.org/10.7554/eLife.20914

Further reading

    1. Structural Biology and Molecular Biophysics
    Mrityunjay Singh, Dinesh C Indurthi ... Shailendra Asthana
    Research Advance

    Agonists enhance receptor activity by providing net-favorable binding energy to active over resting conformations, with efficiency (η) linking binding energy to gating. Previously, we showed that in nicotinic receptors, η-values are grouped into five structural pairs, correlating efficacy and affinity within each class, uniting binding with allosteric activation (Indurthi and Auerbach, 2023). Here, we use molecular dynamics (MD) simulations to investigate the low-to-high affinity transition (L→H) at the Torpedo α−δ nicotinic acetylcholine receptor neurotransmitter site. Using four agonists spanning three η-classes, the simulations reveal the structural basis of the L→H transition where: the agonist pivots around its cationic center (‘flip’), loop C undergoes staged downward displacement (‘flop’), and a compact, stable high-affinity pocket forms (‘fix’). The η derived from binding energies calculated in silico matched exact values measured experimentally in vitro. Intermediate states of the orthosteric site during receptor activation are apparent only in simulations, but could potentially be observed experimentally via time-resolved structural studies.

    1. Structural Biology and Molecular Biophysics
    Aivaras Vaškevičius, Denis Baronas ... Daumantas Matulis
    Research Article

    We designed novel pre-drug compounds that transform into an active form that covalently modifies particular His residue in the active site, a difficult task to achieve, and applied to carbonic anhydrase (CAIX), a transmembrane protein, highly overexpressed in hypoxic solid tumors, important for cancer cell survival and proliferation because it acidifies tumor microenvironment helping invasion and metastases processes. The designed compounds have several functionalities: (1) primary sulfonamide group recognizing carbonic anhydrases (CA), (2) high-affinity moieties specifically recognizing CAIX among all CA isozymes, and (3) forming a covalent bond with the His64 residue. Such targeted covalent compounds possess both high initial affinity and selectivity for the disease target protein followed by complete irreversible inactivation of the protein via covalent modification. Our designed prodrug candidates bearing moderately active pre-vinylsulfone esters or weakly active carbamates optimized for mild covalent modification activity to avoid toxic non-specific modifications and selectively target CAIX. The lead inhibitors reached 2 pM affinity, the highest among known CAIX inhibitors. The strategy could be used for any disease drug target protein bearing a His residue in the vicinity of the active site.